ALPMY:OTC-Astellas Pharma Inc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 9.64

Change

0.00 (0.00)%

Market Cap

USD 16.79B

Volume

5.25K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-07 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBF Roche Holding AG

N/A

USD 248.88B
RHHBY Roche Holding Ltd ADR

N/A

USD 248.79B
RHHVF Roche Holding AG Participation

N/A

USD 248.79B
AZNCF AstraZeneca PLC

N/A

USD 214.99B
SNYNF Sanofi

N/A

USD 127.02B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 93.38B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 45.22B
ALPMF Astellas Pharma Inc

N/A

USD 17.22B
RICFY Recordati Industria Chimica e ..

N/A

USD 14.03B
CSPCY CSPC Pharmaceutical Group Limi..

N/A

USD 8.62B

ETFs Containing ALPMY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.21% 25% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.21% 25% F 41% F
Trailing 12 Months  
Capital Gain -4.65% 32% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.65% 32% F 47% F
Trailing 5 Years  
Capital Gain -43.46% 31% F 40% F
Dividend Return 3.60% 23% F 8% B-
Total Return -39.86% 28% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -11.25% 33% F 25% F
Dividend Return -11.25% 27% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.24% 67% D+ 86% B+
Risk Adjusted Return -58.49% 27% F 13% F
Market Capitalization 16.79B 58% F 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.